|
| Tuesday, 20 December 2022, 20:50 HKT/SGT | |
| |
|
|
|
HONG KONG, Dec 20, 2022 - (ACN Newswire) - Pharmaron (300759:SZ; 3759:HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With around 17,000 employees and operations in China, U.S. and U.K., Pharmaron have an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.
Green and Low carbon have remained the keywords during Pharmaron's development. Pharmaron set its first five-year environmental targets in 2016 and achieved a reduction of water consumption and energy consumption per RMB10,000 of output value by 25% and 20% in 2020, respectively, which showed solid results in energy savings and emissions reduction. In 2021, Pharmaron further developed the 2021-2025 Environmental Targets based on the characteristics of its industry and align with the United Nations (UN)'s advocacy for climate action, as well as the peak carbon emissions and carbon neutrality targets of the countries where it operates. Pharmaron will continue to take concrete actions toward the targets and further improve its environmental management system, resource savings exercises, waste & pollutant reduction effort, and green facility upgrades. Moreover, Pharmaron will continuously promote green chemistry practices and establish more suitable and efficient processes to reduce waste and pollutants.
At the corporate level, Pharmaron incorporated ESG governance into the overall corporate governance and operations and is committed to continuously improving its ESG governance and management systems through updating the policies and systems, initiating targeted campaigns, increasing operational transparency, etc. According to its 2021 Environmental, Social and Governance Report, as the global COVID-19 pandemic continued, Pharmaron's team continues to be guided by its mission "to support its partners' success in discovery, development and commercialization of innovative medicines" and continue to develop its fully integrated end-to-end clinical service platform.
Pharmaron built a three-tiered ESG governance with clear responsibilities to ensure the effective implementation of its ESG strategies. In addition, Pharmaron places a high emphasis on interactions and alignment of priorities with stakeholders on various ESG topics, through regular questionnaire surveys and interviews, to better address the expectations of different stakeholders.
Pharmaron provides its customers with high-quality, high-value-added services and novel solutions. Its quality assurance system seamlessly manages the entire product lifecycle from customer acceptance through raw material procurement, R&D service execution, and quality inspection to R&D product delivery and more; its complete set of information security management strategies serves to protect information security and ensure the confidentiality, integrity, and availability of the information assets; its five-level intellectual property rights (IPR) protection system consisting of Management Safeguard, Policy Safeguard, Legal Document Safeguard, Training Safeguard, and Technical Safeguard was effective in delivering reinforced IPR protection. It remained committed to Honesty, Credibility, Mutual Benefit and Win-Win principles when engaging with its suppliers. It managed and controlled environmental and social risks in the supply chain relating to core issues, such as business integrity, business information security, supply chain labour rights, and supply chain environmental protection. It implemented transparent procurement to maintain a fair environment for its prospective suppliers.
The research and development of new medicines are fundamental to human health and wellness. In the coming year, Pharmaron will, as always, fulfil its responsibilities to all stakeholders including the society, environment, investors/shareholders, employees, customers, supply chain, etc. It will follow its ESG commitments to being green, sustainable and transparent as well as strive to continuously improve economic, environmental and social sustainability.
Contact:
e: bd@pharmaron.com
u: www.pharmaron.com
Beijing, China and Waltham, Mass.
Topic: Press release summary
Sectors: Chemicals, Spec.Chem, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Friday, December 12, 2025 10:00:00 AM
|
|
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Thursday, December 11, 2025 10:15:00 PM
|
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT/SGT
|
|
|
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing
Dec 11, 2025 18:09 HKT/SGT
|
|
|
Nasdaq Verafin Joins Global Anti-Scam Alliance
Dec 11, 2025 14:21 HKT/SGT
|
|
|
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards
Dec 11, 2025 12:54 HKT/SGT
|
|
|
Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating
Dec 11, 2025 08:20 HKT/SGT
|
|
|
Indonesian Government's Swift Response in Recovering Flood-hit Sumatra 
Dec 10, 2025 23:30 HKT/SGT
|
|
|
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline
Dec 10, 2025 21:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
